Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Transparency and Access for Healthcare Consumers

Transparency in healthcare is vital to help avoid or reduce the varying disparities that exist and continue to burden the overall medical field in this country. Technology in healthcare is growing and has mitigated some of these disparities, even helping close some of the gaps that have been magnified. But there is still more progress…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Highway to Health on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Transparency in healthcare is vital to help avoid or reduce the varying disparities that exist and continue to burden the overall medical field in this country. Technology in healthcare is growing and has mitigated some of these disparities, even helping close some of the gaps that have been magnified. But there is still more progress to be made and seen as access remains a top concern.

What kinds of technological advances can help improve healthcare access?

Discussing this subject on the newest episode of Highway to Health, host David Kemp interviewed Paul Ketchel, CEO and Co-Founder of MDSave, a platform that helps healthcare consumers compare and weigh medical costs and prices. The two talked about the state of healthcare today, what areas need improvement, and how his company offers resolutions to some of the issues facing the healthcare industry.

Kemp and Ketchel further explored the topic and talked about …

  1. Ketchel’s background and building a healthcare platform
  2. Ways in which technology is a problem solver
  3. Why and where healthcare technology falls behind in creating access

Ketchel detailed how innovative ideas drive change and how it’s benefitted his own, and naturally his company.

“For me innovation is, you know, using the newest technological advances and tools to solve what has traditionally been very large, difficult problems, or problems we haven’t been able to solve in the past. And fortunately, for companies like mine and maybe unfortunately for the rest of the world, healthcare is full of those problems, and I always tell folks I feel like one thing that’s been disappointing from the view of an innovator is that we’ve not really applied that technology to a lot of areas in healthcare yet,” he said.

He continued, “Things are getting better and we’re trying, but you know I think it’s safe to say we’re probably 20 solid years behind other sectors,” said Ketchel.

Paul Ketchel is the CEO and Co-Founder of MDSave, Inc., which he helped found in 2012. Before co-founding the company, he was the COO of Diagnostix Network Alliance, LLC for two years and had other roles in government relations and business development. Ketchel is an alumnus of University of Tennessee-Knoxville where here he received a degree in political science.

Highway to Health

Part of this channel

Highway to Health

Healthcare innovation conversations for executives and technology buyers.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

Blair Health raises CAD $4.24M to expand its LLM-guided specialty care workflows

Blair Health raises CAD $4.24M to expand its LLM-guided specialty care workflows

Blair Health raised CAD $4.24 million in a pre-seed round, according to Fierce Healthcare. It plans to expand protocol-driven virtual specialty care across Canada and the U.S.

  • 01Blair Health raised CAD $4.24 million in pre-seed funding.
  • 02Qualified Health positions its AI platform around safety and governance, including clinician oversight, auditability and traceability, according to Fierce Healthcare.

Sep 23, 2026

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512